Calliditas Therapeutics: In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action

STOCKHOLM, May 16, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day

Related Keywords

Stockholm ,Sweden ,United States ,Leicester ,United Kingdom ,American ,Jonathan Barratt ,Garethj Thomas ,Gareth Thomas ,Phd University Hospital Southampton ,Renal Research Group ,Life Sciences ,University Of Leicester ,American Society Of Nephrology Kidney Health Initiative ,Iga Nephropathy Network ,University Of Southampton ,Rare Disease Group ,Inderes Event Studio ,University Hospital Southampton ,Experimental Pathology ,United Kingdom National Registry ,Rare Kidney Diseases ,In Ternational Iga Nephropathy ,Chief Investigator ,American Society ,Nephrology Kidney Health Initiative ,Identifying Surrogate Endpoints ,Clinical Trials ,Iga Nephropathy Work ,Ihr Portfolio ,Calliditas ,Herapeutics ,Person ,Irtual ,Anti ,Fibrotic ,Effects ,Setanaxib ,Tarpeyo ,Mode ,Action ,